Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 37Gynecologic 2Tumor-Agnostic 1Other 1Head & Neck 1Genitourinary 1Gastrointestinal 1

Conditions

Sexual Dysfunctions, Psychological 1Breast Neoplasms 1

Interventions

Tirzepatide 5Educational Status 4Transcutaneous Electric Nerve Stimulation 2Resistance Training 2Radiotherapy 2Mouthwashes 2Methods 2Megestrol Acetate 2Early Intervention, Educational 2Counseling 2semaglutide 1naldemedine 1mirabegron 1ma zi ren wan 1exemestane 1Xylitol 1Weights and Measures 1Vitamin D 1Tablets 1Stents 1Standard of Care 1Spermine Synthase 1Specimen Handling 1Psychiatric Rehabilitation 1Progestins 1Practice Guidelines as Topic 1Population Groups 1Nutrition Assessment 1Negative-Pressure Wound Therapy 1Mindfulness 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
exemestane × Other × 90 days × Clear all
NCT07596212 2026-05-19

BRE-06: Study to Increase Tolerance to Aromatase Inhibitors for Patients With Early-Stage Hormone Receptor Positive Breast Cancer Who Developed Hypoactive Sexual Desire Disorder

University of Illinois at Chicago

Phase 1/2 Not yet recruiting
100 enrolled
BreastOther

Breast Neoplasms, Sexual Dysfunctions, Psychological

Data powered by HemOnc (CC BY 4.0) Colophon âš¡